Skip to content
Search

Latest Stories

Support urged for unsuccessful Pharmacy candidates as GPhC declares results

Support urged for unsuccessful Pharmacy candidates as GPhC declares results
The GPhC and PDA are emphasize the need for robust support systems for candidates who sat the June 2024 registration assessment for pharmacists, offering guidance on mental health resources and the appeals process for those who were unsuccessful

In light of the recently announced results of the June 2024 registration assessment for pharmacists, Duncan Rudkin, Chief Executive of the General Pharmaceutical Council (GPhC) acknowledged the importance of a robust support network for candidates who did not clear the assessment.

The results announced on Tuesday (30) and jointly published by (GPhC) and the Pharmaceutical Society of Northern Ireland (PSNI) revealed that 695 out of 2,776 candidates were unsuccessful while 75 per cent successfully passed the assessment, highlighting the challenges faced by a significant portion of aspiring pharmacists.


In a statement Rudkin emphasised that failing the assessment does not mark the end of the journey, stating:

"The registration assessment is one of the ways we test trainee pharmacists to ensure they understand how to apply knowledge appropriately and in a timely way. This means they can make professional judgements when practising.

“For those who unfortunately didn’t pass the assessment, there are a range of options available, with all the relevant information on the June 2024 registration assessment page."

Furthermore, he pointed to various resources available to help candidates navigate this difficult period.

"The charity Pharmacist Support can also provide help with mental health and wellbeing as well as practical advice," Rudkin added.

Pharmacist Support provides vital assistance, including mental health and wellbeing services, which are crucial for candidates grappling with the emotional impact of not passing the assessment.

Additionally, the charity offers practical advice on next steps, including career guidance and strategies for preparing to retake the assessment.

For many candidates, particularly those who were sitting the exam for a second or third time, the pressure can be overwhelming.

The pass rates for these groups were notably lower, with only 53 per cent of second-time sitters and 59 per cent of third-time sitters passing.

This underscores the need for targeted interventions to help these candidates overcome the hurdles they face.

As the pharmacy profession continues to evolve, the GPhC and other stakeholders are being urged to ensure that all trainees, especially those who struggle, have access to the support they need.

This includes not only academic and professional guidance but also emotional and mental health resources.

Rudkin also congratulated successful candidates to passed the assessment in June.

A total of 2,776 candidates sat for the assessment, with 2,081 successfully passing, yielding an overall pass rate of 75 per cent.

"Many congratulations to the candidates who passed this year’s registration assessment. It is the culmination of years of hard work and part of the journey to becoming a registered pharmacist," he said.

Decline in success rates

The June 2024 assessment results show a slight decline in the pass rate compared to previous years, with 2023 recording a pass rate of 77 per cent, and 2022 a higher 80 per cent .

Of the 2,678 candidates who sat under the GPhC jurisdiction, 2,358 were first-time sitters, with 77 per cent of them passing.

Second-time sitters had a pass rate of 53 per cent, while third-time sitters had a pass rate of 59 per cent.

In addition to emotional and practical support, the Pharmacists' Defence Association (PDA) has reminded candidates of their right to appeal if they believe there were procedural errors or exceptional circumstances that affected their performance.

The PDA advises candidates to thoroughly review the GPhC’s guidance on appeals and gather all necessary evidence before proceeding.

"The PDA would like to remind all candidates who sat the June 2024 assessment, and feel that they have grounds to appeal on receipt of their results, to review the GPhC guidance and gather all evidence before taking action," the PDA stated.

The appeal process is strict, with valid grounds limited to procedural errors or exceptional circumstances unknown to the candidate at the time of the exam.

Appeals must be submitted by 5 pm on Tuesday, 20 August 2024, with supporting evidence provided in a clear format.

More For You

NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
AAH upgrades ordering portal, making procurement easier for pharmacies

AAH Cascade compares prices and availability across suppliers

AAH Warehouse

AAH upgrades ordering portal to improve product visibility

Leading pharmaceutical wholesaler AAH Pharmaceuticals Ltd has introduced new digital functionalities to AAH Cascade, its independently managed ordering portal, making procurement easier and more cost-effective for pharmacies.

AAH Cascade compares product prices and availability across multiple suppliers, eliminating the need for manual searches.

Keep ReadingShow less
Majority of Brits neglect consistent skincare routine,  survey finds

On average, Brits go to bed without washing their face twice a week.

Photo credit: gettyimages

Skincare: One in five Brits go to bed without washing their face daily, survey finds

Nearly two-thirds of Brits (60 per cent) neglect a consistent skincare routine,with almost one in five going to bed without washing their face daily, according to a new survey by consumer health company Kenvue.

The UK-wide survey of 2,000 people revealed that one-third of respondents (34 per cent) spend five minutes or less on their daily skincare routine. On average, Brits go to bed without washing their face twice a week.

Keep ReadingShow less
Risk of pharmacy closures remains despite record funding uplift

Community pharmacy sector remains in a fragile position as the funding gap is still significant, says CCA.

gettyimages

Pharmacy closures still a risk as funding deal fails to cover costs – warns CCA

The community pharmacy sector has secured the largest funding uplift across the NHS, yet concerns remain that it may not be enough to prevent further closures and service reductions.

Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a £3.073 billion funding package for 2025/26, supplemented by an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less